Search Details

Word: biotechs (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...This man was a member of Democratic Governor’s Association, the Midwest Governor’s Association, the Governor’s Ethanol Coalition, and the Governor’s Biotech Partnership. He refuses to join any groups that don’t have the word “Governor” in their titles...

Author: By Meaghan E Lyons, CONTRIBUTING WRITER | Title: The Fellowship of the IOP | 10/8/2008 | See Source »

...long-term goal is to harness the real power of Boston that no place in the world can compete with,” Ingber said. “The ability to interact with faculty across Harvard, its hospitals and its neighboring universities, the big pharmaceutical companies and biotech start-ups, the IT companies—Boston...

Author: By June Q. Wu, CRIMSON STAFF WRITER | Title: Harvard Receives $125 Million for Biological Engineering | 10/7/2008 | See Source »

...years here.” Tara A. Dunn ’01, was the only woman to be awarded a Life Science Fellowship this year. She spent some time after college working for a health care strategy consulting firm called Health Advances. The firm worked with pharmaceutical companies, biotech firms, and nonprofits, looking at how different health care firms could optimize treatment delivery opportunities. “I definitely knew that I wasn’t interested in being a lab scientist,” Dunn said, “I wanted to work at the intersection of business...

Author: By Prateek Kumar, CRIMSON STAFF WRITER | Title: HBS Names First Life Sci. Fellows | 10/5/2008 | See Source »

...obstacles still lie ahead for RNAi-based drugs, not least of which is how to best deliver them to patients. To solve that question, Roche turned to the outside. Last year Roche bought a 5% stake in Alnylam, a biotech start-up based in Cambridge, Mass., that's a leader in understanding RNAi...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

...some estimates--but the deal will almost definitely go through. Nonetheless, Roche will have to work hard to hang on to Genentech's laid-back culture, one that has always attracted top minds. "They know there won't be the same flexibility and creativity Genentech is known for," says biotech analyst Geoff Porges of Sanford C. Bernstein & Co. "Roche is perhaps the industry's most brilliant acquirer, but it has never shown it can innovate internally...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next